Results of the DRCR Network Protocol T - Efficacy of Aflibercept in DME Treatment

The DRCR Network Protocol T is a study comparing aflibercept, ranibizumab and bevacizumab for diabetic macular oedema (DME). The study, conducted under the U.S. NIH, evaluated visual gains over 1 and 2 years. Aflibercept provided significant and clinically meaningful gains compared to ranibizumab and bevacizumab. At Year 1, aflibercept outperformed others in vision gains, requiring fewer rescue laser treatments, which was sustained up to Year 2. The area-under-the-curve analysis confirmed aflibercept’s overall best performance in achieving and sustaining visual improvements in patients with baseline vision worse than 20/50.